| Literature DB >> 26903992 |
Admilton G de Oliveira1, Flavia R Spago1, Ane S Simionato1, Miguel O P Navarro1, Caroline S da Silva1, André R Barazetti1, Martha V T Cely1, Cesar A Tischer2, Juca A B San Martin3, Célia G T de Jesus Andrade3, Cláudio R Novello4, João C P Mello4, Galdino Andrade1.
Abstract
Citrus canker is a very destructive disease of citrus species. The challenge is to find new compounds that show strong antibiotic activity and low toxicity to plants and the environment. The objectives of the present study were (1) to extract, purify and evaluate the secondary metabolites with antibiotic activity produced by Pseudomonas aeruginosa LV strain in vitro against Xanthomonas citri subsp. citri (strain 306), (2) to determine the potential of semi-purified secondary metabolites in foliar application to control citrus canker under greenhouse conditions, and (3) to identify antibiotic activity in orange leaf mesophyll infected with strain 306, by electron microscopy. Two pure bioactive compounds were isolated, an organocopper antibiotic compound (OAC) and phenazine-1-carboxamide. Phenazine-1-carboxamide did not show any antibiotic activity under the experimental conditions used in this study. The OAC showed a high level of antibiotic activity with a minimum inhibitory concentration of 0.12 μg mL(-1). In greenhouse tests for control of citrus canker in orange trees, the semi-purified fraction F3d reduced lesion formation by about 97%. The concentration used was 500 times lower than that for the recommended commercial copper-based product. Electron microscopy showed that F3d altered the exopolysaccharide matrix and caused cell lysis of the pathogen inside the citrus canker lesions. These results suggest that secondary metabolites produced by inducing P. aeruginosa LV strain have a high potential to be used as a bioproduct to control citrus canker.Entities:
Keywords: Pseudomonas secondary metabolites; antibiotic activity; bioactive compounds; citrus canker; purification process
Year: 2016 PMID: 26903992 PMCID: PMC4746251 DOI: 10.3389/fmicb.2016.00113
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Antibiotic activity against Xcc 306 by disk diffusion technique of fractions and pure compound obtained from purification of extract containing secondary metabolites produced by Pseudomonas aeruginosa LV strain.
| Concentration (μg disk-1) | Fractions | Purified compounds | |||||
|---|---|---|---|---|---|---|---|
| FD | F3 | F3d | F3d.3 | F3d.3.4 | F3d.3.4.2 (OAC) | F3d.3.4.4 (PCN) | |
| 1,000 | 21.5 ± 1 | 26.5 ± 1 | ∗ | ∗ | ∗ | ∗ | ∗ |
| 100 | ∗ | ∗ | 32 ± 0.5 | 42 ± 1 | ∗ | ∗ | ∗ |
| 30 | ∗ | ∗ | ∗ | ∗ | 39 ± 0.5 | 67 ± 0.5 | - |
| NC | - | - | - | - | - | - | - |
Determination of minimum inhibitory concentration of fractions and pure compounds obtained from secondary metabolites produced by Pseudomonas aeruginosa LV strain, against Xcc 306.
| Sample | MIC (μg mL-1) |
|---|---|
| DP | 78.12 |
| F3 | 19.53 |
| F3d | 6.25 |
| F3d.3.4.2 (OAC) | 0.12 |
| NC | – |